Strategies and prospects for vaccination against the hepatitis C viruses.
Houghton
M
M
Chiron Corporation, Emeryville, CA 94608, USA.
D000818:Animals; D006023:Glycoproteins / Q000276:immunology; D016174:Hepacivirus / Q000276:immunology; D006526:Hepatitis C / Q000517:prevention & control*; D006801:Humans; D002679:Pan troglodytes; D011994:Recombinant Proteins / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
C087035:E1 protein, Hepatitis C virus; D006023:Glycoproteins; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014761:Viral Hepatitis Vaccines; C091015:glycoprotein E2, Hepatitis C virus